Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Therapy with Immunomodulator MGN1703 in Extensive-Disease Small Cell Lung Cancer
2013-003503-19Phase 2Completed
- Sponsor
- Mologen AG
- Start
- Oct 2013
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of lefitolimod in small cell lung cancer (SCLC) (2 arms), sponsored by Mologen AG. Primary endpoint: Overall survival from randomization. Started Oct 2013; status: completed.
02
Drugs
lefitolimod
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2013-003503-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003503-19.